Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 21-hydroxylase deficiency
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: It remains controversial whether long-term glucocorticoids are charged of bone demineralization in patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The aim of this study was to know whether cumulative glucocorticoid dose from the diagnosis in childhood to adulthood in patients with CAH had a negative impact on bone mineral density (BMD). DESIGN: This was a retrospective study. METHODS: Thirty-eight adult patients with classical and non-classical CAH were included. BMD was measured in the lumbar spine and femoral neck. Total cumulative glucocorticoid (TCG) and total average glucocorticoid (TAG) doses were calculated from pediatric and adult files. RESULTS: We showed a difference between final and target heights (-0.82+/-0.92 s.d. for women and -1.31+/-0.84 s.d. for men; P<0.001). Seventeen patients (44.7%) had bone demineralization (35.7% of women and 70% of men). The 28 women had higher BMD than the 10 men for lumbar (-0.26+/-1.20 vs -1.25+/-1.33 s.d.; P=0.02) and femoral T-scores (0.21+/-1.30 s.d. versus -1.08+/-1.10 s.d.; P=0.007). In the salt-wasting group, women were almost significantly endowed with a better BMD than men (P=0.053). We found negative effects of TCG, TAG on lumbar (P<0.001, P=0.002) and femoral T-scores (P=0.006, P<0.001), predominantly during puberty. BMI was protective on BMD (P=0.006). CONCLUSION: The TCG is an important factor especially during puberty for a bone demineralization in patients with 21-hydroxylase deficiency. The glucocorticoid treatment should be adapted particularly at this life period and preventive measures should be discussed in order to limit this effect.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Using the WHO definition of reduced BMD 16, the prevalence of reduced BMD in previous CAH studies ranges between 45–60% 3, 4, 17 as compared to 52% in our cohort.”
From Cortical bone mineral density in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency (2015) · cites this paper as [17]
In the citing paper
“Chakhtoura et al. (266) showed a negative correlation between the cumulative lifetime GC dose and BMD.”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [266]
Citations
Cites
Variations in pattern of pubertal changes in girls
Marshall, W. A., & Tanner, J. M. (1969) · Archives of Disease in Childhood · doi:10.1136/adc.44.235.291 · Cited by 5,963 · cited 1×
“The onset of puberty was noted (B2 in girls (16) and testes size greater than 20 x 30 mm in boys (17)) as well as height and bone age at the beginning of puberty.”
BackgroundVariations in the pattern of pubertal changes in boys
Marshall, W. A., & Tanner, J. M. (1970) · Archives of Disease in Childhood · doi:10.1136/adc.45.239.13 · Cited by 5,147 · cited 1×
“The onset of puberty was noted (B2 in girls (16) and testes size greater than 20 x 30 mm in boys (17)) as well as height and bone age at the beginning of puberty.”
BackgroundCongenital adrenal hyperplasia due to 21-hydroxylase deficiency*
White, P. C., & Speiser, P. W. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.3.0398 · Cited by 1,432
Morishima, A., Grumbach, M. M., Simpson, E. R., Fisher, C., & Qin, K. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.12.8530621 · Cited by 1,416 · cited 1×
“Authors of published papers explained that estrogens have more protective action for bone mineralization than androgen (36, 41), which could contribute to this result, all the more since the majority of women took exogenous estrogens.”
BackgroundThe epidemiology of corticosteroid-induced osteoporosis: a meta-analysis
Staa, T. P. V., Staa, T. P. V., Staa, T. P. V., Leufkens, H. G. M., & Cooper, C. (2002) · Osteoporosis International · doi:10.1007/s001980200108 · Cited by 1,294 · cited 2×
“work on 81 patients in 2 randomized, double-masked, placebo-controlled trials (23), where they related the TCG to the bone loss.”
BackgroundBuckley, T. M., & Schatzberg, A. F. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1056 · Cited by 964 · cited 1×
“Indeed, it reduces basal ACTH and 17-OHP by inhibiting hypothalamic–adrenal–pituitary axis ( 49 ).”
BackgroundCongenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency
White, P. C. (2000) · Endocrine Reviews · doi:10.1210/er.21.3.245 · Cited by 877
Clinical Use of Bone Densitometry: Scientific Review
Cummings, S. R., Bates, D., & Black, D. M. (2002) · JAMA · doi:10.1001/jama.288.15.1889 · Cited by 817
Prader, A., Largo, R. H., Molinari, L., & Issler, C. (1989) · PubMed · Cited by 814
Standards for Children's Height at Ages 2-9 Years Allowing for Height of Parents
Tanner, J. M., Goldstein, H., & Whitehouse, R. H. (1970) · Archives of Disease in Childhood · doi:10.1136/adc.45.244.755 · Cited by 812
Research works printed but not linked: 4
- 2006, Journal of Clinical Endocrinology & Metabolism, 3, 865
- 1989, Helvetica paediatrica acta, 52, 1
- 1995, Journal of Clinical Endocrinology & Metabolism, 80, 2238
- Michel, 1993, The Journal of Rheumatology, 20, 1666
Cited by
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
“(234) showed a negative correlation between the accumulated lifetime dose of GC and BMD.”
Speiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients
Arlt, W., Willis, D. S., Wild, S. H., Krone, N., Doherty, E. J., Hahner, S., Han, T. S., Carroll, P. V., Conway, G. S., Rees, D. A., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0917 · Cited by 506
PW, S., W, A., RJ, A., LS, B., GS, C., DP, M., HFL, M.-B., WL, M., MH, M., SE, O., et al. (2019) · Yearbook of Paediatric Endocrinology · doi:10.1530/ey.16.8.5 · Cited by 300
TASK channel deletion in mice causes primary hyperaldosteronism
Davies, L. A., Hu, C., Guagliardo, N. A., Sen, N., Chen, X., Talley, E. M., Carey, R. M., Bayliss, D. A., & Barrett, P. Q. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712000105 · Cited by 198
Increased mortality in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Falhammar, H., Frisén, L., Norrby, C., Hirschberg, A. L., Almqvist, C., Nordenskjöld, A., & Nordenström, A. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2957 · Cited by 196
Nordenström, A., & Falhammar, H. (2019) · European Journal of Endocrinology · doi:10.1530/eje-18-0712 · Cited by 158
Congenital Adrenal Hyperplasia
Witchel, S. F., & Azziz, R. (2011) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2010.10.001 · Cited by 161
Clinical perspectives in congenital adrenal hyperplasia due to 11β-hydroxylase deficiency
Bulsari, K., & Falhammar, H. (2016) · Endocrine · doi:10.1007/s12020-016-1189-x · Cited by 149
“However, it can be extrapolated from the available data for 21OHD that BMD can be negatively affected with long-term glucocorticoid exposure in an unphysiological manner [68, 74, 106, 126, 127].”
BackgroundNonclassic Congenital Adrenal Hyperplasia
Witchel, S. F., & Azziz, R. (2010) · International Journal of Pediatric Endocrinology · doi:10.1155/2010/625105 · Cited by 101
“Available data, derived from outcome reports for individuals with classic CAH, are inconsistent due to varying glucocorticoid doses, potential compliance issues, and subject heterogeneity [65, 66].”
BackgroundFalhammar, H., & Nordenström, A. (2015) · Endocrine · doi:10.1007/s12020-015-0656-0 · Cited by 127
Approach to the patient: the adult with congenital adrenal hyperplasia
Auchus, R. J., & Arlt, W. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1440 · Cited by 121
“In 1 study, bone mass correlated inversely with the cumulative dose of glucocorticoid (12).”
BackgroundHealth Problems in Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency
Reisch, N., Arlt, W., & Krone, N. (2011) · Hormone Research in Paediatrics · doi:10.1159/000327794 · Cited by 106
Modified-Release Hydrocortisone in Congenital Adrenal Hyperplasia
Merke, D. P., Mallappa, A., Arlt, W., Brac de la Perriere, A., Lindén Hirschberg, A., Juul, A., Newell-Price, J., Perry, C. G., Prete, A., Rees, D. A., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab051 · Cited by 109
Self-citationClinical outcomes in the management of congenital adrenal hyperplasia
Falhammar, H., & Thorén, M. (2012) · Endocrine · doi:10.1007/s12020-011-9591-x · Cited by 106
Falhammar, H., Butwicka, A., Landén, M., Lichtenstein, P., Nordenskjöld, A., Nordenström, A., & Frisén, L. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3707 · Cited by 98
Bone mineral density, bone markers, and fractures in adult males with congenital adrenal hyperplasia
Falhammar, H., Filipsson Nyström, H., Wedell, A., Brismar, K., & Thorén, M. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-0865 · Cited by 82
Management considerations for the adult with congenital adrenal hyperplasia
Auchus, R. J. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.01.039 · Cited by 65
Bone Health in Disorders of Sex Differentiation
Bertelloni, S., Baroncelli, G., & Mora, S. (2010) · Sexual Development · doi:10.1159/000315961 · Cited by 64
“…Hagenfeldt et al., 2000; Paganini et al., 2000], femoral neck [Jääskeläinen and Voutilainen, 1996; Bachelot et al., 2007; Falhammar et al., 2007; Chakhtoura et al., 2008], or whole skeleton [Hagenfeldt et al., 2000; King et al., 2006; Sciannamblo et al.; 2006; Falhammar et al., 2007] in women…”
BackgroundResultInfluentialClinical advances in the pharmacotherapy of congenital adrenal hyperplasia
Prete, A., Auchus, R. J., & Ross, R. J. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-0794 · Cited by 62
El‐Maouche, D., Collier, S., Prasad, M., Reynolds, J. C., & Merke, D. P. (2015) · Clinical Endocrinology · doi:10.1111/cen.12507 · Cited by 53
Congenital adrenal hyperplasia – pharmacologic interventions from the prenatal phase to adulthood
Claahsen-van der Grinten, H. L., Stikkelbroeck, N. M. M. L., Otten, B. J., & Hermus, A. R. M. M. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.05.004 · Cited by 53
Long-Term Outcome of Patients With Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency
Mnif, M. F., Kamoun, M., Mnif, F., Charfi, N., Kallel, N., Naceur, B. B., Rekik, N. M., Abid, M., Mnif, Z., Sfar, M. H., et al. (2012) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31824369e4 · Cited by 54
“It is suggestive that low BMD is associated with glucocorticoid overtreatment, especially during infancy and childhood.(39) However, increased BMI, common in CAH, may be protective for bone, and episodes of androgen excess may have an anabolic effect on bone.”
BackgroundThe diagnosis and treatment of adrenal insufficiency during childhood and adolescence
Park, J., Didi, M., & Blair, J. (2016) · Archives of Disease in Childhood · doi:10.1136/archdischild-2015-308799 · Cited by 47
Negative impact of polycystic ovary syndrome on bone health: a systematic review and meta-analysis
Piovezan, J. M., Premaor, M. O., & Comim, F. V. (2019) · Human Reproduction Update · doi:10.1093/humupd/dmz020 · Cited by 50
Bachelot, A., Golmard, J. L., Dulon, J., Dahmoune, N., Leban, M., Bouvattier, C., Cabrol, S., Leger, J., Polak, M., & Touraine, P. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-0978 · Cited by 46
Self-citationZimmermann, A., Sido, P. G., Schulze, E., Al Khzouz, C., Lazea, C., Coldea, C., & Weber, M. M. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03518.x · Cited by 45
Long-Term Outcomes of Congenital Adrenal Hyperplasia
Nordenström, A., Lajić, S., & Falhammar, H. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1528 · Cited by 50
“Androgen excess seemed to improve BMD in both adult females and young patients with CAH [50,53].”
InfluentialChallenges in treatment of patients with non-classic congenital adrenal hyperplasia
Adriaansen, B. P. H., Schröder, M. A. M., Span, P. N., Sweep, F. C. G. J., van Herwaarden, A. E., & der Grinten, H. L. C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1064024 · Cited by 51
“This is also illustrated in several studies where higher bone quality or BMD is reported in NCCAH patients compared to classic CAH patients (85, 89, 105, 107, 108).”
ResultSchaeffer, T. L., Tryggestad, J. B., Mallappa, A., Hanna, A., Krishnan, S., Chernausek, S. D., Chalmers, L. J., Reiner, W. G., Kropp, B. P., & Wisniewski, A. B. (2010) · International Journal of Pediatric Endocrinology · doi:10.1155/2010/692439 · Cited by 45
Falhammar, H., Frisén, L., Hirschberg, A. L., Nordenskjöld, A., Almqvist, C., & Nordenström, A. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab712 · Cited by 42
Ceccato, F., Barbot, M., Albiger, N., Zilio, M., De Toni, P., Luisetto, G., Zaninotto, M., Greggio, N. A., Boscaro, M., Scaroni, C., et al. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0104 · Cited by 42
Li, L., Bensing, S., & Falhammar, H. (2021) · Endocrine · doi:10.1007/s12020-021-02723-z · Cited by 37
Sarafoglou, K., Merke, D. P., Reisch, N., der Grinten, H. L. C., Falhammar, H., & Auchus, R. J. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad134 · Cited by 36
Growth and Reproductive Outcomes in Congenital Adrenal Hyperplasia
Nebesio, T. D., & Eugster, E. A. (2010) · International Journal of Pediatric Endocrinology · doi:10.1155/2010/298937 · Cited by 34
“[33] France 2008 38 −0.”
ResultAuer, M. K., Paizoni, L., Hofbauer, L. C., Rauner, M., Chen, Y., Schmidt, H., Huebner, A., Bidlingmaier, M., & Reisch, N. (2020) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2020.105734 · Cited by 33
“Similar gender differences in terms of BMD in CAH patients have been reported before [26] and may be due to sex-different effects of adrenal androgen exposure on bone health.”
Congenital adrenal hyperplasia in adults
Auchus, R. J. (2010) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32833961d7 · Cited by 30
Russian clinical practice guidelines «congenital adrenal hyperplasia»
Mokrysheva, N. G., Mel'nichenko, G. A., Adamyan, L. V., Troshina, E. A., Молашенко, Н. В., Игоревна, С. А., Uvarova, E. V., Esayan, E. R. M., Andreeva, E. N., Ужегова, Ж. А., et al. (2021) · Obesity and metabolism · doi:10.14341/omet12787 · Cited by 31
Long‐term health consequences of congenital adrenal hyperplasia
Pofi, R., Ji, X., Krone, N. P., & Tomlinson, J. (2023) · Clinical Endocrinology · doi:10.1111/cen.14967 · Cited by 30
“28,143,144 Previous studies in patients with CAH showed that GC actual and cumulative dose, 134,144 – 146 long ‐ acting GC formulations 146,147 and reverse circadian regimens all negatively impact BMD. 15 Importantly, a 2 ‐ year prospective, single ‐ centre study in patients with primary adrenal…”
Congenital Adrenal Hyperplasia
Fraga, N. R., Minaeian, N., & Kim, M. S. (2024) · Pediatrics in Review · doi:10.1542/pir.2022-005617 · Cited by 31
Bachelot, A., Chakhtoura, Z., Samara-Boustani, D., Dulon, J., Touraine, P., & Polak, M. (2010) · International Journal of Pediatric Endocrinology · doi:10.1155/2010/326275 · Cited by 21
Self-citationSubstitution therapy in adult patients with congenital adrenal hyperplasia
Reisch, N. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.11.002 · Cited by 24
Congenital adrenal hyperplasia
Demirci, C., & Witchel, S. F. (2008) · Dermatologic Therapy · doi:10.1111/j.1529-8019.2008.00216.x · Cited by 24
“reported that total cumulative glucocorticoid dose and total average glucocorticoid dose were associated with lower lumbar and femoral T-scores; increased body mass index (BMI) appeared to have a protective effect on bone mineral density (46).”
BackgroundDiagnosis and management of classical congenital adrenal hyperplasia
Marumudi, E., Khadgawat, R., Surana, V., Shabir, I., Joseph, A. A., & Ammini, A. C. (2013) · Steroids · doi:10.1016/j.steroids.2013.04.007 · Cited by 23
“The few studies that have assessed bone mineral density (BMD) in patients with CAH have been in heterogeneous population and have shown contradictory results [48,49].”
Herath, M., Langdahl, B. L., Ebeling, P. R., & Milat, F. (2021) · Clinical Endocrinology · doi:10.1111/cen.14637 · Cited by 21
“In YAs with CAH, including a cohort of premenopausal women aged 20–29 years(68) cumulative glucocorticoid dose is associated with low BMD; men with 21‐hydroxylase deficiency have lower spinal BMD than women.(70,71) Degraded TBS is associated with higher hydrocortisone doses and may be more prevalent than low BMD in CA…”
Backgroundder Grinten, H. L. C., Adriaansen, B. P. H., & Falhammar, H. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae718 · Cited by 19
Choi, J., & Yoo, H. (2017) · Korean Journal of Pediatrics · doi:10.3345/kjp.2017.60.2.31 · Cited by 17
Adrenogenitales Syndrom und Wachstumshormonmangel: Betreuung beim Übergang zum Erwachsenenalter
Dörr, H. G., & Schöfl, C. (2009) · Der Internist · doi:10.1007/s00108-009-2401-3 · Cited by 17
Simon, A. B., Brener, A., Segev‐Becker, A., Yackobovitch‐Gavan, M., Uretzky, A., Davidov, A. S., Alaev, A., Oren, A., Eyal, O., Weintrob, N., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1022752 · Cited by 17
“Each patient’s total cumulative hydrocortisone dose was determined by compiling these annual cumulative hydrocortisone doses (43).”
BackgroundLoli, P., Menotti, S., di Filippo, L., & Giustina, A. (2025) · Endocrine · doi:10.1007/s12020-025-04341-5 · Cited by 16
Lee, D. H., Kong, S. H., Jang, H. N., Ahn, C. H., Lim, S. G., Lee, Y. A., Kim, S. W., & Kim, J. H. (2022) · Archives of Osteoporosis · doi:10.1007/s11657-022-01090-0 · Cited by 11
“showed a negative correlation between cumulative lifetime GC dose and BMD in patients with CAH [22].”
BackgroundBone mineral density in young adult women with congenital adrenal hyperplasia
Jyotsna, V., Raizada, N., Upadhyay, A. D., & Gupta, N. C. (2015) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.172283 · Cited by 12
“[16] Total cumulative glucocorticoid dose was an important factor for low BMD in both classic and nonclassic CAH patients.[17]”
BackgroundGao, Y., Wang, O., Guan, W., Wu, X., Mao, J., Wang, X., Yu, W., & Nie, M. (2021) · Clinical Endocrinology · doi:10.1111/cen.14391 · Cited by 11
Shaikh, A. M. A., Alghanmi., Y., Awidah, S., Bahha, A., Ahmed, M., & Soliman, A. T. (2019) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_99_19 · Cited by 12
Iervolino, L. L., Ferraz‐de‐Souza, B., Martin, R. M., Costa, F. C., de Miranda, M. C., Mendonca, B. B., & Bachega, T. A. S. S. (2020) · Osteoporosis International · doi:10.1007/s00198-019-05268-0 · Cited by 11
McDougall, D., Bhibhatbhan, A., & Toth, C. C. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2009.01190.x · Cited by 9
“Increased appetite (leading to weight gain) 61 (29) Psychological (insomnia, elevated mood, psychosis) 44 (21) Impaired glucose tolerance 29 (14) Osteoporosis 26 (12) Gastrointestinal (gastritis, gastroesophageal reflux, gastroduodenal ulceration) 26 (12)”
BackgroundBone Mineral Density in Children and Adolescents with Congenital Adrenal Hyperplasia
Alves-Junior, P. A. G., Gilban, D., de Mendonça, L. M. C., Farias, M. L. F., & Beserra, I. C. R. (2014) · International Journal of Endocrinology · doi:10.1155/2014/806895 · Cited by 10
Bone Mineral Density in Patients With Congenital Adrenal Hyperplasia From Prepubertal to Adult Age
Stancampiano, M. R., Pitea, M., Maruca, K., Meroni, S. L. C., Bucolo, C., Russo, G., & Mora, S. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf123 · Cited by 8
Amr, N. H., Mahmoud, R. A. A., Youssef, O., Toaima, N. N., & Elsedfy, H. H. (2020) · Clinical Endocrinology · doi:10.1111/cen.14333 · Cited by 8
“Age at start glucocorticoid therapy (mo) Median (IQR) 2 (1-6) 5 (1.”
BackgroundBechtold, S., Beyerlein, A., Bonfig, W., Dalla Pozza, R., Putzker, S., Otto, R., Schmidt, H., & Schwarz, H. P. (2014) · Hormone Research in Paediatrics · doi:10.1159/000362759 · Cited by 7
Bone safety of dual-release hydrocortisone in patients with autoimmune primary adrenal insufficiency
Bioletto, F., Barale, M., Parasiliti‐Caprino, M., Giannelli, J., Campioni, L., Cappiello, V., Carlo, M. C. D., Ghigo, E., Massimo, P., & Giordano, R. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1234237 · Cited by 8
“A decrease in bone mineral density (BMD) and an increase in fracture risk have been reported in adult patients receiving C-GC replacement therapy for either primary adrenal insufficiency (PAI), secondary adrenal insufficiency (SAI) or congenital adrenal hyperplasia (CAH) (16–18); moreover, a correlation between these…”
BackgroundGanesh, R., Suresh, N., Janakiraman, L., & Ravikumar, K. G. (2015) · The Indian Journal of Pediatrics · doi:10.1007/s12098-015-1835-y · Cited by 7
Wiromrat, P., Namphaisan, P., Wongsurawat, N., Panamonta, O., & Nasomyont, N. (2022) · Clinical Endocrinology · doi:10.1111/cen.14809 · Cited by 6
“While most studies demonstrated no relationship between duration or cumulative dose of GC and BMD,(26) some studies demonstrated an inverse relationship.(7,9,35) There has been only one study evaluating the longitudinal changes in BMD in CAH individuals.”
BackgroundÜnal, S., Alikaşifoğlu, A., Özön, A., Gonc, N. E., & Kandemir, N. (2020) · The Turkish Journal of Pediatrics · doi:10.24953/turkjped.2020.03.002 · Cited by 6
Bachelot, A., & Touraine, P. A. (2014) · La Presse Médicale · doi:10.1016/j.lpm.2013.10.006 · Cited by 7
Self-citationThe way toward adulthood for females with nonclassic congenital adrenal hyperplasia
Ntali, G., Charisis, S., Kylafi, C. F., Vogiatzi, E., & Michala, L. (2021) · Endocrine · doi:10.1007/s12020-021-02715-z · Cited by 4
Pathophysiology and evaluation of bone health in adrenal diseases
Uygur, M. M., di Filippo, L., Frara, S., Menotti, S., & Giustina, A. (2025) · Endocrine · doi:10.1007/s12020-025-04260-5 · Cited by 5
Bone Mineral Content and Density in Indian Children with Congenital Adrenal Hyperplasia
Ganesh, R., Suresh, N., & Janakiraman, L. (2018) · Indian Pediatrics · doi:10.1007/s13312-018-1400-7 · Cited by 5
“[9] reported that BMD was mostly affected by glucocorticoid therapy during puberty [9].”
BackgroundResultHyperplasie congénitale des surrénales: les formes précoces
Samara‐Boustani, D., Bachelot, A., Pinto, G., Thibaud, E., Touraine, P. A., & Polak, M. (2009) · EMC - Pédiatrie - Maladies infectieuses · doi:10.1016/s1637-5017(09)72438-x · Cited by 4
Self-citationShifman, B. M., Dzeranova, L. K., Pigarova, E. A., Tiulpakov, A. N., & Fedorova, N. S. (2019) · Obesity and metabolism · doi:10.14341/omet10032 · Cited by 3
Widodo, A. D., Batubara, J. R. L., Ifran, E. K. B., Akib, A. A., Pardede, S. O., & Setyanto, D. B. (2016) · Sari Pediatri · doi:10.14238/sp12.5.2011.307-14 · Cited by 2
Congenital Adrenal Hyperplasia in the Adolescent
Kim, M. S., Liang, M. C., Kokorowski, P. K., Tseng, T., Koppin, C. M., & Geffner, M. E. (2023) · Springer eBooks · doi:10.1007/978-3-031-14881-1_59 · Cited by 2
Ryabets‐Lienhard, A., Nguyen, J. N., Pickering, T. A., Fraga, N. R., Deras, E. A., Geffner, M. E., & Kim, M. S. (2025) · Hormone Research in Paediatrics · doi:10.1159/000548651 · Cited by 1
Rare Causes of Pediatric Primary Adrenal Insufficiency: An Observational Cohort Study
Schermesser-Sicard, M., Samara‐Boustani, D., Roucher‐Boulez, F., Pinto, G., Carel, J., Quoc, A. N., Vermillac, G., Rovani, S., Thalassinos, C., Costa, S., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.05.011 · Cited by 1
Self-citationMartín, S., Muñoz, L., Pérez, A., Sobrero, G. M., Picotto, G., Ochetti, M., Carpentieri, A. R., Silvano, L. K., de Barboza, G. D., Signorino, M., et al. (2014) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2014-0104 · Cited by 1
Congenital Adrenal Hyperplasia in the Adolescent
Kim, M. S., Tseng, T., Koppin, C. M., & Geffner, M. E. (2016) · Springer eBooks · doi:10.1007/978-3-319-17002-2_59-1 · Cited by 1
Steroid Replacement in Adrenal Insufficiency
Blair, J., Debono, M., & Ross, R. J. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64307-6 · Cited by 1
(2008) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32831c7e5c · Cited by 1
Ganesh, R., Suresh, N., Janakiraman, L., & Ravikumar, K. G. (2016) · The Indian Journal of Pediatrics · doi:10.1007/s12098-016-2155-6 · Cited by 1
“Long term glucocorticoid therapy produces bone loss in the following ways: [A] Direct suppression of osteoblastic activity [B] Inhibiting calcium absorption from the gut, thereby leading to secondary hyperparathyroidism and increasing bone resorption by the osteoclasts [C] Inhibiting renal tubular calcium resorption […”
BackgroundHiperplasia suprarrenal congénita: formas precoces
Samara‐Boustani, D., Bachelot, A., Pinto, G., Thibaud, E., Touraine, P. A., & Polak, M. (2010) · EMC - Pediatría · doi:10.1016/s1245-1789(10)70185-2
Self-citationPrise en charge à l’âge adulte des patients avec un bloc en 21 hydroxylase
Christin‐Maître, S. (2013) · Médecine Nucléaire · doi:10.1016/j.mednuc.2012.11.002
Self-citationCongenital Adrenal Hyperplasia in the Adolescent
Kim, M. S., Tseng, T., Koppin, C. M., & Geffner, M. E. (2017) · Springer eBooks · doi:10.1007/978-3-319-17798-4_59
Management of Adult Patients With Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency
Grouthier, V., Dulon, J., Bachelot, A., & Touraine, P. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.66140-8
Self-citationCongenital Adrenal Hyperplasia in the Adolescent
Kim, M. S., Liang, M. C., Kokorowski, P. K., Tseng, T., Koppin, C. M., & Geffner, M. E. (2022) · Springer eBooks · doi:10.1007/978-3-319-17002-2_59-2
Management of adult patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Grouthier, V., Dulon, J., Bachelot, A., & Touraine, P. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00132-1
Self-citationSteroid replacement in adrenal insufficiency
Blair, J., Debono, M., & Ross, R. J. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00147-3
Adrenal Insufficiency: Diagnostic Approaches, Treatments, and Outcomes Volume II
(2025) · Frontiers research topics · doi:10.3389/978-2-8325-7003-6
Metadata
- Authors
- Chakhtoura, Z., Bachelot, A., Samara-Boustani, D., Ruiz, J.-C., Donadille, B., Dulon, J., Christin-Maître, S., Bouvattier, C., Raux-Demay, M.-C., Bouchard, P., Carel, J.-C., Leger, J., Kuttenn, F., Polak, M., & Touraine, P.
- Affiliations
- Assistance Publique – Hôpitaux de Paris (FR)
- ORCID
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-06
- Volume
- 158
- Issue
- 6
- Pages
- 879-887
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2126029954
- Cited by
- 90
- References
- 48
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 3 · 2023: 4 · 2022: 7 · 2021: 6 · 2020: 5 · 2019: 4 · 2018: 5 · 2017: 2 · 2016: 5 · 2015: 5 · 2014: 7 · 2013: 4 · 2012: 4
- FWCI
- 3.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- 10th European Congress of Endocrinology
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Keywords
- 21-hydroxylase deficiency, congenital adrenal hyperplasia, glucocorticoid therapy, cumulative glucocorticoid dose, bone mineral density, bone demineralization, puberty, sex differences, body mass index, salt-wasting CAH, lumbar spine, femoral neck
- MeSH terms
- Adolescent, Adrenal Hyperplasia, Congenital, Adult, Body Height, Female, Glucocorticoids, Humans, Male, Puberty, Retrospective Studies, Steroid 21-Hydroxylase, Absorptiometry, Photon, Bone Density
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.